What are the limitations of the perioperative anticoagulation bridging?

While the perioperative anticoagulation bridging is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the perioperative anticoagulation bridging to ensure safe bedside use and optimal diagnostic accuracy.

How does the perioperative anticoagulation bridging compare to other Hematology scores?

The perioperative anticoagulation bridging is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the perioperative anticoagulation bridging free to use?

Yes. OpiCalc provides the perioperative anticoagulation bridging completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

Perioperative Anticoagulation Bridging

Anticoagulation Bridging: Assessment of thrombotic vs. bleeding risk. The modern standard (BRIDGE trial) favors holding therapy without heparin coverage for most patients.

1. Primary Condition

2. Risk Granularity

CHA₂DS₂-VASc Score0

Consensus Strategy

No Bridging Needed

Thrombotic Risk

Low Risk

The risk of major bleeding from bridging outperforms the thrombotic benefit. Hold VKA as per surgery type.

Procedural Risk Integration Advised

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Defining the need for heparin bridging (LMWH/UFH) in patients on Vitamin K Antagonists (Warfarin) undergoing surgery.

Assessing the thrombotic risk of interrupting anticoagulation.

Reducing the hazard of perioperative thromboembolism vs. major bleeding.

The 'BRIDGE' Trial Shift

The BRIDGE trial demonstrated that for the majority of patients with AF (low-to-moderate risk), bridging does not reduce stroke but SIGNIFICANTLY increases major bleeding. Bridging is now reserved for "High Risk" cohorts only.

Section 2

Formula & Logic

Thrombotic Risk Classes

Risk Class	AF (CHA₂DS₂-VASc)	VTE History	Mechanical Valve
High (Bridge)	≥ 7 or recent Stroke	VTE < 3 months ago	Any Mitral Valve
Moderate	5 - 6	VTE 3 - 12 months ago	Aortic (bileaflet) + risk factor
Low (No Bridge)	0 - 4	VTE > 12 months ago	Aortic (bileaflet)

Post-Op Restart

Following high-bleeding-risk surgery, wait 48–72 hours before restarting full-dose anticoagulation.

Section 3

Pearls/Pitfalls

DOACs & Bridging

Bridging is NOT recommended for DOACs (Apixaban/Rivaroxaban). Because of their rapid onset/offset, we simply hold the dose for 24–48 hours based on CrCl and the bleeding risk of the surgery (per PAUSE protocol).

Section 4

Evidence Appraisal

Primary Score

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Douketis JD et al. • NEJM. 2015;373(9):823-33.

View Source

Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.

Douketis JD et al. • Chest. 2022;Support for "No Bridging" in low-to-moderate AF.

View Source

Section 5

Literature

Paradigm Shift

Moving away from the "Fear of Stroke" (which led to over-bridging) toward an evidence-based "Fear of Bleed," as perioperative bleeds themselves increase long-term mortality.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Defining the need for heparin bridging (LMWH/UFH) in patients on Vitamin K Antagonists (Warfarin) undergoing surgery.

Assessing the thrombotic risk of interrupting anticoagulation.

Reducing the hazard of perioperative thromboembolism vs. major bleeding.

The 'BRIDGE' Trial Shift

Section 2

Formula & Logic

Thrombotic Risk Classes

Risk Class	AF (CHA₂DS₂-VASc)	VTE History	Mechanical Valve
High (Bridge)	≥ 7 or recent Stroke	VTE < 3 months ago	Any Mitral Valve
Moderate	5 - 6	VTE 3 - 12 months ago	Aortic (bileaflet) + risk factor
Low (No Bridge)	0 - 4	VTE > 12 months ago	Aortic (bileaflet)

Post-Op Restart

Following high-bleeding-risk surgery, wait 48–72 hours before restarting full-dose anticoagulation.

Section 3

Pearls/Pitfalls

DOACs & Bridging

Section 4

Evidence Appraisal

Primary Score

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Douketis JD et al. • NEJM. 2015;373(9):823-33.

View Source

Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.

Douketis JD et al. • Chest. 2022;Support for "No Bridging" in low-to-moderate AF.

View Source

Section 5

Literature

Paradigm Shift

Moving away from the "Fear of Stroke" (which led to over-bridging) toward an evidence-based "Fear of Bleed," as perioperative bleeds themselves increase long-term mortality.

Last Comprehensive Review: 2026

Related Hematology Tools

HbS Percentage Target Calculator

ITP Bleeding Score

IWG ITP Response Criteria

WHO Bleeding Scale

Thrombocytopaenia Differential

Warfarin Dose Calculator

DOAC Dose Selector

DOAC Renal Dose Adjustment

Heparin Nomogram

Anti-Xa Monitoring Interpreter

Have feedback about this calculator?Let us know.

Perioperative Anticoagulation Bridging

Anticoagulation Bridging: Assessment of thrombotic vs. bleeding risk. The modern standard (BRIDGE trial) favors holding therapy without heparin coverage for most patients.

1. Primary Condition

2. Risk Granularity

CHA₂DS₂-VASc Score0

Consensus Strategy

No Bridging Needed

Thrombotic Risk

Low Risk

The risk of major bleeding from bridging outperforms the thrombotic benefit. Hold VKA as per surgery type.

Procedural Risk Integration Advised

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Defining the need for heparin bridging (LMWH/UFH) in patients on Vitamin K Antagonists (Warfarin) undergoing surgery.

Assessing the thrombotic risk of interrupting anticoagulation.

Reducing the hazard of perioperative thromboembolism vs. major bleeding.

The 'BRIDGE' Trial Shift

Section 2

Formula & Logic

Thrombotic Risk Classes

Risk Class	AF (CHA₂DS₂-VASc)	VTE History	Mechanical Valve
High (Bridge)	≥ 7 or recent Stroke	VTE < 3 months ago	Any Mitral Valve
Moderate	5 - 6	VTE 3 - 12 months ago	Aortic (bileaflet) + risk factor
Low (No Bridge)	0 - 4	VTE > 12 months ago	Aortic (bileaflet)

Post-Op Restart

Following high-bleeding-risk surgery, wait 48–72 hours before restarting full-dose anticoagulation.

Section 3

Pearls/Pitfalls

DOACs & Bridging

Section 4

Evidence Appraisal

Primary Score

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Douketis JD et al. • NEJM. 2015;373(9):823-33.

View Source

Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.

Douketis JD et al. • Chest. 2022;Support for "No Bridging" in low-to-moderate AF.

View Source

Section 5

Literature

Paradigm Shift

Moving away from the "Fear of Stroke" (which led to over-bridging) toward an evidence-based "Fear of Bleed," as perioperative bleeds themselves increase long-term mortality.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Defining the need for heparin bridging (LMWH/UFH) in patients on Vitamin K Antagonists (Warfarin) undergoing surgery.

Assessing the thrombotic risk of interrupting anticoagulation.

Reducing the hazard of perioperative thromboembolism vs. major bleeding.

The 'BRIDGE' Trial Shift

Section 2

Formula & Logic

Thrombotic Risk Classes

Risk Class	AF (CHA₂DS₂-VASc)	VTE History	Mechanical Valve
High (Bridge)	≥ 7 or recent Stroke	VTE < 3 months ago	Any Mitral Valve
Moderate	5 - 6	VTE 3 - 12 months ago	Aortic (bileaflet) + risk factor
Low (No Bridge)	0 - 4	VTE > 12 months ago	Aortic (bileaflet)

Post-Op Restart

Following high-bleeding-risk surgery, wait 48–72 hours before restarting full-dose anticoagulation.

Section 3

Pearls/Pitfalls

DOACs & Bridging

Section 4

Evidence Appraisal

Primary Score

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Douketis JD et al. • NEJM. 2015;373(9):823-33.

View Source

Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.

Douketis JD et al. • Chest. 2022;Support for "No Bridging" in low-to-moderate AF.

View Source

Section 5

Literature

Paradigm Shift

Moving away from the "Fear of Stroke" (which led to over-bridging) toward an evidence-based "Fear of Bleed," as perioperative bleeds themselves increase long-term mortality.

Last Comprehensive Review: 2026

Related Hematology Tools

HbS Percentage Target Calculator

ITP Bleeding Score

IWG ITP Response Criteria

WHO Bleeding Scale

Thrombocytopaenia Differential

Warfarin Dose Calculator

DOAC Dose Selector

DOAC Renal Dose Adjustment

Heparin Nomogram

Anti-Xa Monitoring Interpreter

Have feedback about this calculator?Let us know.